Annual FCF
-$325.71 M
-$100.64 M-44.71%
December 31, 2023
Summary
- As of February 7, 2025, MDGL annual free cash flow is -$325.71 million, with the most recent change of -$100.64 million (-44.71%) on December 31, 2023.
- During the last 3 years, MDGL annual FCF has fallen by -$167.81 million (-106.28%).
- MDGL annual FCF is now -1409.54% below its all-time high of $24.87 million, reached on December 31, 2007.
Performance
MDGL Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
-$67.76 M
+$72.31 M+51.62%
September 30, 2024
Summary
- As of February 7, 2025, MDGL quarterly free cash flow is -$67.76 million, with the most recent change of +$72.31 million (+51.62%) on September 30, 2024.
- Over the past year, MDGL quarterly FCF has increased by +$72.31 million (+51.62%).
- MDGL quarterly FCF is now -200.38% below its all-time high of $67.51 million, reached on December 31, 2007.
Performance
MDGL Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
-$438.32 M
+$17.50 M+3.84%
September 30, 2024
Summary
- As of February 7, 2025, MDGL TTM free cash flow is -$438.32 million, with the most recent change of +$17.50 million (+3.84%) on September 30, 2024.
- Over the past year, MDGL TTM FCF has increased by +$17.50 million (+3.84%).
- MDGL TTM FCF is now -1546.36% below its all-time high of $30.31 million, reached on June 30, 2016.
Performance
MDGL TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
MDGL Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -44.7% | +51.6% | +3.8% |
| 3 y3 years | -106.3% | +51.6% | +3.8% |
| 5 y5 years | -1175.8% | +51.6% | +3.8% |
MDGL Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -76.9% | at low | -40.7% | +54.7% | -138.1% | +3.8% |
| 5 y | 5-year | -679.3% | at low | -445.8% | +54.7% | -948.7% | +3.8% |
| alltime | all time | -1409.5% | at low | -200.4% | +54.7% | -1546.4% | +3.8% |
Madrigal Pharmaceuticals Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$67.76 M(-51.6%) | -$438.32 M(-3.8%) |
| Jun 2024 | - | -$140.08 M(-6.3%) | -$455.82 M(+16.5%) |
| Mar 2024 | - | -$149.51 M(+84.7%) | -$391.12 M(+20.1%) |
| Dec 2023 | -$325.71 M(+44.7%) | -$80.97 M(-5.0%) | -$325.71 M(+7.4%) |
| Sep 2023 | - | -$85.26 M(+13.1%) | -$303.28 M(+9.4%) |
| Jun 2023 | - | -$75.38 M(-10.4%) | -$277.13 M(+6.9%) |
| Mar 2023 | - | -$84.10 M(+43.7%) | -$259.21 M(+15.2%) |
| Dec 2022 | -$225.07 M(+22.2%) | -$58.54 M(-0.9%) | -$225.07 M(+4.8%) |
| Sep 2022 | - | -$59.10 M(+2.9%) | -$214.69 M(+6.7%) |
| Jun 2022 | - | -$57.46 M(+15.0%) | -$201.20 M(+5.6%) |
| Mar 2022 | - | -$49.97 M(+3.7%) | -$190.62 M(+3.5%) |
| Dec 2021 | -$184.13 M(+16.6%) | -$48.16 M(+5.6%) | -$184.13 M(-3.6%) |
| Sep 2021 | - | -$45.61 M(-2.7%) | -$190.92 M(-1.2%) |
| Jun 2021 | - | -$46.88 M(+7.8%) | -$193.17 M(+13.3%) |
| Mar 2021 | - | -$43.47 M(-20.9%) | -$170.55 M(+8.0%) |
| Dec 2020 | -$157.90 M(+277.8%) | -$54.96 M(+14.8%) | -$157.90 M(+36.9%) |
| Sep 2020 | - | -$47.85 M(+97.2%) | -$115.35 M(+46.3%) |
| Jun 2020 | - | -$24.27 M(-21.3%) | -$78.82 M(+19.3%) |
| Mar 2020 | - | -$30.82 M(+148.2%) | -$66.10 M(+58.1%) |
| Dec 2019 | -$41.80 M(+63.7%) | -$12.42 M(+9.7%) | -$41.80 M(+17.2%) |
| Sep 2019 | - | -$11.32 M(-1.9%) | -$35.65 M(+20.5%) |
| Jun 2019 | - | -$11.54 M(+77.0%) | -$29.58 M(+26.4%) |
| Mar 2019 | - | -$6.52 M(+3.9%) | -$23.40 M(-8.3%) |
| Dec 2018 | -$25.53 M(+13.8%) | -$6.27 M(+19.5%) | -$25.53 M(+1.3%) |
| Sep 2018 | - | -$5.25 M(-2.0%) | -$25.20 M(+1.2%) |
| Jun 2018 | - | -$5.36 M(-38.0%) | -$24.90 M(-8.8%) |
| Mar 2018 | - | -$8.64 M(+45.4%) | -$27.31 M(+21.7%) |
| Dec 2017 | -$22.44 M(+27.4%) | -$5.95 M(+20.1%) | -$22.44 M(+3.0%) |
| Sep 2017 | - | -$4.95 M(-36.3%) | -$21.78 M(-16.5%) |
| Jun 2017 | - | -$7.77 M(+106.0%) | -$26.07 M(+24.5%) |
| Mar 2017 | - | -$3.77 M(-28.6%) | -$20.95 M(+18.9%) |
| Dec 2016 | -$17.61 M(+460.5%) | -$5.28 M(-42.9%) | -$17.61 M(+31.2%) |
| Sep 2016 | - | -$9.24 M(+249.2%) | -$13.43 M(-144.3%) |
| Jun 2016 | - | -$2.65 M(+504.3%) | $30.31 M(+99.4%) |
| Mar 2016 | - | -$438.00 K(-60.0%) | $15.20 M(-583.6%) |
| Dec 2015 | -$3.14 M | -$1.10 M(-103.2%) | -$3.14 M(-85.3%) |
| Sep 2015 | - | $34.49 M(-294.2%) | -$21.32 M(-71.3%) |
| Jun 2015 | - | -$17.76 M(-5.4%) | -$74.41 M(-4.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2015 | - | -$18.77 M(-2.6%) | -$77.55 M(-1.9%) |
| Dec 2014 | -$79.07 M(+1.1%) | -$19.27 M(+3.6%) | -$79.07 M(+0.6%) |
| Sep 2014 | - | -$18.60 M(-11.0%) | -$78.57 M(+2.6%) |
| Jun 2014 | - | -$20.90 M(+3.0%) | -$76.57 M(+0.8%) |
| Mar 2014 | - | -$20.29 M(+8.1%) | -$75.98 M(-2.8%) |
| Dec 2013 | -$78.18 M(+43.1%) | -$18.77 M(+13.1%) | -$78.18 M(+8.6%) |
| Sep 2013 | - | -$16.60 M(-18.3%) | -$72.02 M(+4.5%) |
| Jun 2013 | - | -$20.31 M(-9.7%) | -$68.88 M(+11.6%) |
| Mar 2013 | - | -$22.49 M(+78.4%) | -$61.73 M(+13.0%) |
| Dec 2012 | -$54.64 M(+13.9%) | -$12.61 M(-6.4%) | -$54.64 M(+3.3%) |
| Sep 2012 | - | -$13.47 M(+2.4%) | -$52.90 M(+2.7%) |
| Jun 2012 | - | -$13.16 M(-14.6%) | -$51.51 M(+1.9%) |
| Mar 2012 | - | -$15.40 M(+41.7%) | -$50.54 M(+5.3%) |
| Dec 2011 | -$47.99 M(+25.2%) | -$10.87 M(-10.1%) | -$47.99 M(+5.8%) |
| Sep 2011 | - | -$12.08 M(-0.9%) | -$45.36 M(+8.6%) |
| Jun 2011 | - | -$12.19 M(-5.1%) | -$41.77 M(+8.2%) |
| Mar 2011 | - | -$12.85 M(+56.0%) | -$38.59 M(+0.7%) |
| Dec 2010 | -$38.34 M(+40.6%) | -$8.24 M(-3.0%) | -$38.34 M(+2.8%) |
| Sep 2010 | - | -$8.49 M(-5.7%) | -$37.30 M(+0.6%) |
| Jun 2010 | - | -$9.01 M(-28.4%) | -$37.09 M(-28.3%) |
| Mar 2010 | - | -$12.59 M(+74.7%) | -$51.70 M(+89.6%) |
| Dec 2009 | -$27.26 M(-32.0%) | -$7.21 M(-13.0%) | -$27.26 M(+540.6%) |
| Sep 2009 | - | -$8.28 M(-64.9%) | -$4.26 M(-73.8%) |
| Jun 2009 | - | -$23.62 M(-299.4%) | -$16.25 M(+33.6%) |
| Mar 2009 | - | $11.84 M(-25.1%) | -$12.16 M(-69.7%) |
| Dec 2008 | -$40.12 M(-261.3%) | $15.80 M(-177.9%) | -$40.12 M(-446.5%) |
| Sep 2008 | - | -$20.27 M(+3.8%) | $11.58 M(-26.7%) |
| Jun 2008 | - | -$19.54 M(+21.2%) | $15.79 M(-29.6%) |
| Mar 2008 | - | -$16.11 M(-123.9%) | $22.43 M(-9.8%) |
| Dec 2007 | $24.87 M(-145.6%) | $67.51 M(-520.2%) | $24.87 M(-158.3%) |
| Sep 2007 | - | -$16.07 M(+24.6%) | -$42.63 M(+60.5%) |
| Jun 2007 | - | -$12.90 M(-5.7%) | -$26.57 M(+94.3%) |
| Mar 2007 | - | -$13.67 M(-3.7%) | -$13.67 M(-3.7%) |
| Dec 2006 | -$54.56 M(-18.3%) | - | - |
| Dec 2005 | -$66.77 M(+88.7%) | - | - |
| Mar 2005 | - | -$14.20 M | -$14.20 M |
| Dec 2004 | -$35.39 M(+45.1%) | - | - |
| Dec 2003 | -$24.38 M | - | - |
FAQ
- What is Madrigal Pharmaceuticals annual free cash flow?
- What is the all time high annual FCF for Madrigal Pharmaceuticals?
- What is Madrigal Pharmaceuticals annual FCF year-on-year change?
- What is Madrigal Pharmaceuticals quarterly free cash flow?
- What is the all time high quarterly FCF for Madrigal Pharmaceuticals?
- What is Madrigal Pharmaceuticals quarterly FCF year-on-year change?
- What is Madrigal Pharmaceuticals TTM free cash flow?
- What is the all time high TTM FCF for Madrigal Pharmaceuticals?
- What is Madrigal Pharmaceuticals TTM FCF year-on-year change?
What is Madrigal Pharmaceuticals annual free cash flow?
The current annual FCF of MDGL is -$325.71 M
What is the all time high annual FCF for Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals all-time high annual free cash flow is $24.87 M
What is Madrigal Pharmaceuticals annual FCF year-on-year change?
Over the past year, MDGL annual free cash flow has changed by -$100.64 M (-44.71%)
What is Madrigal Pharmaceuticals quarterly free cash flow?
The current quarterly FCF of MDGL is -$67.76 M
What is the all time high quarterly FCF for Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals all-time high quarterly free cash flow is $67.51 M
What is Madrigal Pharmaceuticals quarterly FCF year-on-year change?
Over the past year, MDGL quarterly free cash flow has changed by +$72.31 M (+51.62%)
What is Madrigal Pharmaceuticals TTM free cash flow?
The current TTM FCF of MDGL is -$438.32 M
What is the all time high TTM FCF for Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals all-time high TTM free cash flow is $30.31 M
What is Madrigal Pharmaceuticals TTM FCF year-on-year change?
Over the past year, MDGL TTM free cash flow has changed by +$17.50 M (+3.84%)